Ionis Pharmaceuticals, Inc. IONS
26.58 USD -0.64 (-2.35%)
Regular-session close
26.76 +0.18 +0.68%
After hours · Nov 20, 7:59 PM ET
26.53 Day range 28.07
26.58 52-week range 86.50
- YTD
- -66.40%
- 1 year
- -63.65%
News
marketbeat.com Ionis Pharmaceuticals Pushes TRYNGOLZA Access as Insurer Requirements Slow Launch Ionis Pharmaceuticals NASDAQ: IONS is working to accelerate prescriptions for TRYNGOLZA as physicians gain experience with the drug and patients navigate insurance requirements, CEO Brett Monia said…
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS NEW YORK, Nov. 19, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ionis Pharmaceuticals, Inc. ("Ionis" or the "Company") (NASDAQ: IONS). Such investors are…
zacks.com Ionis' Tryngolza Gets EU Approval for Severe Hypertriglyceridemia IONS expands Tryngolza's European reach as the EU approves its use for sHTG, marking a first for RNA-targeted therapies in this patient population.
benzinga.com Biogen Reports Two-Year Data Showing Diranersen Slows Early Alzheimer's Decline Biogen reports two-year Phase 2 CELIA data showing diranersen slows clinical decline and cuts tau biomarkers in early Alzheimer's disease.benzinga.com Guggenheim Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $65 Guggenheim analyst Debjit Chattopadhyay maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and lowers the price target from $80 to $65.
seekingalpha.com Ionis Pharmaceuticals, Inc. (IONS) Presents at Jefferies Global Healthcare Conference 2026 Transcript Ionis Pharmaceuticals, Inc. (IONS) Presents at Jefferies Global Healthcare Conference 2026 Transcript
businesswire.com Diranersen demonstrates increasing clinical benefit at two years in early Alzheimer's disease CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner, Biogen, shared new data from the Phase 2 CELIA study showing increasing clinical…
gurufocus.com TRYNGOLZA™ (olezarsen) approved in the EU for severe hypertriglyceridemia (sHTG) [url="]Ionis Pharmaceuticals, Inc.[/url] (Nasdaq: IONS) today announced that the European Commission (EC) has approved TRYNGOLZA⢠(olezarsen) as an adjunct tobenzinga.com Ionis’ Tryngolza Wins European Commission Approval For Severe Hypertriglyceridemia, First RNA-Targeted Therapy In EU For Adults With Triglycerides ≥880 Mg/dL – TRYNGOLZA is now the first and only RNA-targeted therapy indicated in the EU for sHTG ≥880 mg/dL (≥10 mmol/L) –– Approximately 700,000 people in the EU5 are estimated to have triglyceride levels…
businesswire.com TRYNGOLZA™ (olezarsen) approved in the EU for severe hypertriglyceridemia (sHTG) CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the European Commission (EC) has approved TRYNGOLZA™ (olezarsen) as an adjunct to diet, in…
marketbeat.com Ionis Pharmaceuticals Sticks to $3 Billion TRYNGOLZA Sales Goal Despite Slow Start Ionis Pharmaceuticals NASDAQ: IONS remains confident that its triglyceride-lowering drug TRYNGOLZA can generate more than $3 billion in peak annual U.S. sales, even as its launch has started more…
gurufocus.com Ionis Pharmaceuticals, Inc. (IONS) Securities Investigation Notice - Levi & Korsinsky Ionis Pharmaceuticals, Inc. (IONS) Securities Investigation Notice - Levi and KorsinskyPR NewswireNEW YORK, Nov. 16, 2026 TRYNGOLZA sales fell to $9.3 million fro
prnewswire.com Ionis Pharmaceuticals, Inc. (IONS) Securities Investigation Notice - Levi & Korsinsky TRYNGOLZA sales fell to $9.3 million from $31.8 million a year earlier, and IONS shares dropped on the product-level numbers. Levi & Korsinsky is investigating potential securities law violations on…
seekingalpha.com Ionis Pharmaceuticals, Inc. (IONS) Presents at UBS Global Biopharma Conference 2026 Transcript Ionis Pharmaceuticals, Inc. ( IONS ) UBS Global Biopharma Conference 2026 November 16, 2026 5:00 AM EST Company Participants Brett Monia - Founder, CEO & Director Conference Call Participants Joon…benzinga.com Goldman Sachs Maintains Neutral on Ionis Pharmaceuticals, Lowers Price Target to $41 Goldman Sachs analyst Salveen Richter maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Neutral and lowers the price target from $58 to $41.
benzinga.com Morgan Stanley Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $75 Morgan Stanley analyst Michael Ulz maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and lowers the price target from $104 to $75.
benzinga.com TD Cowen Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $53 TD Cowen analyst Yaron Werber maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and lowers the price target from $84 to $53.
benzinga.com Oppenheimer Maintains Outperform on Ionis Pharmaceuticals, Lowers Price Target to $70 Oppenheimer analyst Jay Olson maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Outperform and lowers the price target from $85 to $70.
benzinga.com RBC Capital Maintains Outperform on Ionis Pharmaceuticals, Lowers Price Target to $60 RBC Capital analyst Luca Issi maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Outperform and lowers the price target from $85 to $60.
benzinga.com Wells Fargo Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $80 Wells Fargo analyst Yanan Zhu maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and lowers the price target from $95 to $80.
benzinga.com HC Wainwright & Co. Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $70 HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and lowers the price target from $100 to $70.
benzinga.com Why Is Ionis Pharmaceuticals Stock at a 52-Week Low on Monday? Ionis Pharmaceuticals stock hits a 52-week low after halving 2026 Tryngolza guidance, despite beating Q3 earnings estimates and posting 55% revenue growth.
benzinga.com Nasdaq 100 Jumps 3% as Chips Rebound; Nvidia Lags Most Since DeepSeek: Stock Market Today Wall Street rebounds from last week's rout as SOXX jumps 7%, while Nvidia slides on a CEO probe for its worst day versus the S&P 500 since DeepSeek.
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Edesa Biotech (NASDAQ:EDSA) stock moved upwards by 39.0% to $2.98 during Monday's regular session. The market value of their outstanding shares is at $20.6 million. Heron Therapeutics…benzinga.com Ionis Pharmaceuticals Q3 Adj. EPS $(0.40) Beats $(1.21) Estimate, Sales $243.000M Beat $182.117M Estimate Ionis Pharmaceuticals (NASDAQ:IONS) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(1.21) by 66.94 percent. This is a 34.43 percent increase over losses…
benzinga.com Ionis Pharmaceuticals Affirms FY2026 Sales Guidance of $875.000M-$900.000M vs $916.396M Est Ionis Pharmaceuticals (NASDAQ:IONS) affirms FY2026 sales outlook from $875.000 million-$900.000 million to $875.000 million-$900.000 million vs $916.396 million estimate.
benzinga.com KKR, Constellation Energy On Deck Monday As Private Credit, Power Face Test KKR headlines Monday’s reports, with investors weighing whether fundraising momentum can offset a sharp year-to-date stock decline. Constellation Energy, Barrick Mining, Ferguson Enterprises and ORIX…
benzinga.com This CME Group Analyst Turns Bullish; Here Are Top 4 Upgrades For Thursday Analysts upgraded Ionis, CME Group, DigitalOcean, Prologis and Zions Bancorporation, issuing new or revised price targets.benzinga.com BMO Capital Upgrades Ionis Pharmaceuticals to Outperform, Raises Price Target to $66 BMO Capital analyst David Lebowitz upgrades Ionis Pharmaceuticals (NASDAQ:IONS) from Market Perform to Outperform and raises the price target from $54 to $66.
